I usually go on hiatus for the holidays, but I’m starting it a little early this year, because I have a lot going on right now with life in general and some writing deadlines (and a new book coming out next Tuesday). I’ll be back on January 8, 2025 (unless there’s something time-sensitive that occurs…
Author: giniajo@gmail.com
Show me your bobby sox!
Most of “The Transcription Factor BBX Regulates Phosphate Homeostasis” is way beyond my understanding of biochemistry, but I thought we could all use a laugh this week, so it seemed like a good one to share. It’s a serious article, and the researchers are doing really important work — trying to understand why, exactly, bones…
International XLH Day
It’s International XLH Day today, established to raise awareness about the disorder. I always find it a bit challenging to find something to share during awareness campaigns, because I need to be sure that I’m passing on reliable information from reliable sources, so I’m not just muddying the waters more than they already are. As…
More on the diagnostic journey
A few months ago, I wrote about an article on the challenges for patients seeking a timely XLH diagnosis: “The diagnostic odyssey children and adolescents with X-linked hypophosphataemia.” The article was intended to show how data could help clinicians predict the diagnosis based on certain symptoms, but in my reading, it just showed how messy…
Medicare changes
It’s that time of year for anyone on Medicare: open enrollment (October 15 to December 7), when you get deluged with flyers saying “pick me,” and you need to choose your plan (specific insurer) for the coming year. This year, there are a couple overall changes for the better, in terms of capping out of…
New clinical trial
Kyowa Kirin, North America (KKNA) is gearing up for a clinical trial on a new FGF23 antibody, called KK8123 (like burosumab used to be KRN23). The purpose of the trial is to study the new antibody’s safety and effectiveness as doses are increased, presumably to establish an ideal dosage. (The same process was followed in…
What research do you want?
This weekend is the annual meeting of the American Society for Bone and Mineral Research, which, as its name suggests, is the professional organization for researchers who study XLH and other bone disorders. The day before its official start, there’s usually a symposium on rare bone disorders, and this year is no different. There’s nothing…
Side effects
I’m a bit obsessive about reading the labels/inserts for any medications I take, because sometimes I have weird reactions. Many years ago, before I started to pay attention to labels, I was taking Bactrim (antibiotic) for an ear infection, and after a day or two, not only was my ear infection no better, but my…
Back to school
Even decades after graduating from the last of many schools, I still feel like September is a time of fresh starts and new learning. Which is just what we need in the chronic hypophosphatemia world. I often talk about some major XLH-related misconceptions (i.e., it’s purely pediatric, purely bone-related), but there are a number of…
XLH and disability
A while back, I did some posts on applying for disability benefits (not individual legal advice, just general information), but at the time, we had no data on how many #XLH adults were receiving disability benefits, or more generally, any data on the employability picture for us. (You can see the disability benefits posts by…